Roflumilast Indications
Roflumilast has two distinct FDA-approved formulations with separate indications: oral roflumilast 500 mcg tablets for preventing COPD exacerbations in specific patients, and topical roflumilast 0.3% cream for treating plaque psoriasis and seborrheic dermatitis.
Oral Roflumilast (500 mcg tablets)
Primary Indication: COPD Exacerbation Prevention
For patients with moderate to severe COPD with chronic bronchitis and a history of at least one exacerbation in the previous year, oral roflumilast is indicated to prevent acute exacerbations 1. The 2017 ERS/ATS guideline provides more specific criteria: patients should have severe or very severe airflow obstruction (post-bronchodilator FEV1 <50% predicted), symptoms of chronic bronchitis, and exacerbations despite optimal inhaled therapy 2.
Evidence Supporting Use
The evidence demonstrates that roflumilast:
- Reduces moderate and severe exacerbations per patient-year (rate ratio 0.85,95% CI 0.79-0.92) 1
- Particularly effective for severe exacerbations requiring hospitalization (rate ratio 0.76,95% CI 0.60-0.95) 2
- Prolongs time to next exacerbation (hazard ratio 0.88,95% CI 0.81-0.96) 2
- Modestly improves lung function (FEV1 increase of 39-95 mL) 1
Patient Selection Criteria
The clinical trials specifically enrolled patients with:
- FEV1 ≤50% predicted (Grade III or IV obstruction)
- History of chronic bronchitis (chronic cough and sputum production)
- At least one documented exacerbation requiring treatment or hospitalization in the previous year 1
The 2017 GOLD guidelines note that roflumilast is particularly beneficial in patients with chronic bronchitis, severe to very severe COPD, and a history of exacerbations 3.
Important Caveats
Clinicians must counsel patients about significant adverse effects: diarrhea (9.7%), nausea (4.8%), weight loss (8.4% with mean reduction of 2.1 kg), psychiatric symptoms including depression and anxiety (7.1%), and insomnia (3.1%) 2. These side effects lead to treatment discontinuation in approximately 14.9% of patients, particularly in the first 3-4 weeks 1, 2, 1.
Roflumilast should be avoided in underweight patients and used with caution in those with depression 3. The decision to prescribe must also consider limited data on supplemental effectiveness when combined with inhaled corticosteroids 1.
Topical Roflumilast (0.3% cream)
Primary Indications: Dermatologic Conditions
Topical roflumilast 0.3% cream is FDA-approved for two dermatologic conditions:
- Plaque psoriasis (including intertriginous areas) in patients ≥12 years old 4, 5
- Seborrheic dermatitis in patients with mild to moderate disease 6, 7
Evidence for Plaque Psoriasis
In the DERMIS-1 and DERMIS-2 phase 3 trials with 881 patients:
- Investigator Global Assessment (IGA) success rates were 42.4% and 37.5% with roflumilast versus 6.1% and 6.9% with vehicle (P <0.001 for both) 5
- Applied once daily for 8 weeks
- Effective for sensitive areas including skin folds and face 4, 5
- Only 1% discontinued due to adverse reactions 5
Evidence for Seborrheic Dermatitis
Clinical trials demonstrated:
- 79.5% of patients achieved IGA success at week 8 versus 58.0% with vehicle (P <0.001) 6
- Statistically significant reductions in erythema, scaling, and itch severity 6
- Well tolerated with adverse events comparable to vehicle foam 6
Emerging Off-Label Uses
Research reports successful off-label use in hidradenitis suppurativa, recurrent oral aphthosis, nummular eczema, lichen planus, and Behçet disease, though these remain investigational 7.
Drug Interactions and Contraindications
Strong CYP3A4 inhibitors significantly increase roflumilast exposure: ketoconazole increases AUC by 99%, fluvoxamine by 156%, and erythromycin by 70% 8. Strong CYP inducers like rifampicin reduce roflumilast AUC by 79% and should be avoided 8.
Oral contraceptives containing gestodene and ethinyl estradiol increase roflumilast AUC by 51% 8.